{"id":2824,"date":"2017-08-09T02:11:20","date_gmt":"2017-08-09T07:11:20","guid":{"rendered":"https:\/\/issels.com\/blog\/?p=2824"},"modified":"2017-08-09T08:23:43","modified_gmt":"2017-08-09T13:23:43","slug":"fda-quickly-approves-new-one-of-a-kind-cancer-treatment","status":"publish","type":"post","link":"https:\/\/issels.com\/blog\/2017\/08\/09\/fda-quickly-approves-new-one-of-a-kind-cancer-treatment\/","title":{"rendered":"FDA Quickly Approves New One-of-a-Kind Cancer Treatment"},"content":{"rendered":"
\"There
There is New Hope for Cancer Patients.<\/figcaption><\/figure>\n

Researchers have made a number of significant breakthroughs in cancer treatment<\/a>, but a recent development has the healthcare community particularly excited. The Food and Drug Administration (FDA) has approved a drug that treats tumors based on a genetic abnormality<\/a>.<\/p>\n

Keytruda: A Landmark in Immunotherapy for Cancer<\/strong><\/p>\n

Pembrolizumab, marketed under the trade name Keytruda, was tested on a trial group of 86 patients. The results were remarkable: 66 patients saw their tumors shrink and stabilize, while the tumors in 18 of them disappeared with no recurrence.<\/p>\n

What’s different about Keytruda? It’s the first drug that attacks tumors from a shared genetic profile<\/a> rather than the actual location of the tumor. A prospective patient first undergoes testing to determine whether he or she is a genetic match for the mutations targeted by Keytruda.<\/p>\n

Current and Future Possibilities<\/strong><\/p>\n

At present, Keytruda is approved for treating only select forms of advanced bladder, lung and melanoma<\/a> tumors. The drug will be effective for approximately four percent of cancer patients, which still equates to tens of thousands of people.<\/p>\n

Scientists are encouraged by the possibility of further treatment methods tailored to a patient’s specific genetic profile. This ability would greatly enhance development of more accurate targeting and treatment.<\/p>\n

Advanced Immunotherapy for Cancer Treatment from Issels\u00ae<\/strong><\/p>\n

Issels\u00ae uses genomic testing to determine a patient’s individual treatment needs. We then use the information to tailor a personalized immunotherapy for cancer<\/a> program including methods such as vaccines and NK cells.<\/p>\n

We have helped patients with all forms of cancer achieve long-term remission. Contact us<\/a> to learn more about why the Issels\u00ae difference may be right for you.<\/p>\n","protected":false},"excerpt":{"rendered":"

Researchers have made a number of significant breakthroughs in cancer treatment, but a recent development has the healthcare community particularly excited. The Food and Drug Administration (FDA) has approved a drug that treats tumors based on a genetic abnormality. Keytruda: A Landmark in Immunotherapy for Cancer Pembrolizumab, marketed under the trade name Keytruda, was tested … Continue reading FDA Quickly Approves New One-of-a-Kind Cancer Treatment<\/span> →<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[202,203,580,205,538,1],"tags":[367,539],"class_list":["post-2824","post","type-post","status-publish","format-standard","hentry","category-alternative-cancer-treatment","category-cancer-research","category-cancer-treatment","category-immuno-oncology","category-immunotherapy-for-cancer","category-uncategorized","tag-alternative-cancer-therapy","tag-cancer-immunotherapy"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/2824","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/comments?post=2824"}],"version-history":[{"count":3,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/2824\/revisions"}],"predecessor-version":[{"id":2850,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/posts\/2824\/revisions\/2850"}],"wp:attachment":[{"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/media?parent=2824"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/categories?post=2824"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/issels.com\/blog\/wp-json\/wp\/v2\/tags?post=2824"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}